Breast cancer patients – beware! Common breast cancer drug tamoxifen may quadruple your risk of developing a more aggressive cancer in your healthy breast. FOUR times the risk!

A new study (published in Cancer Research) found that tamoxifen therapy brings on a 4.4-fold increased risk of a specific, particularly aggressive form of breast cancer (called estrogen receptor negative contralateral breast cancer)…along with all of its other risks. Risks that include blood clots, stroke, and uterine cancer, just to name a few. On top of those potential risks, about 40% women who do suffer through tamoxifen treatment suffer a cancer recurrence.

Of course, the researchers say this new finding – the four-fold risk of aggressive cancer – is no reason to stop taking tamoxifen, claiming that the benefits outweigh the risks.

Please talk with your doctor about other treatment options. Because chancing a 440% increased risk of more aggressive cancer from a treatment that’s only 60% effective – well, those sound like very bad odds.

Allan Spreen, M.D.
Dr. Allan Spreen, Chief Medical Advisor

Meet the Health Sciences Institute

The Health Sciences Institute (HSI) is an independent organization established in 1998. We’re dedicated to uncovering and researching the most urgent advances in modern underground medicine. Things you WON’T hear about in the mainstream.

Whether they come from a laboratory in Malaysia, a clinic in South America, or a university in Germany, our goal is to bring the treatments that work directly to the people who need them. We alert our Members to exciting breakthroughs in medicine, show them exactly where to go to learn more, and help them understand how they and their families can benefit from these powerful discoveries.

Learn More About the Health Sciences Institute. >